VEGFA and retinopathy of prematurity: In 2011, a multicenter randomized clinical trial demonstrated that intravitreal anti-vascular endothelial growth factor (VEGF) injection was effective for ROP treatment [6], and subsequent reports suggested that intravitreal anti-VEGF injection would have less ocular adverse effects, including myopia and visual field loss, compared with laser treatment [4,7,8].